Eureka Therapeutics, Inc.
52 articles about Eureka Therapeutics, Inc.
-
Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. to its Scientific Advisory Board
11/9/2020
Eureka Therapeutics, Inc. , a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that Randy Schekman, Ph.D., has been appointed to its Scientific Advisory Board. Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine for his ground-breaking work on cell membrane vesicle trafficking. He is currently a Professor in the Department of Molecular and Ce
-
Eureka Therapeutics to Present at Two Upcoming Virtual Conferences
10/13/2020
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that it will participate virtually in two upcoming conferences in October: TCR-based Therapies Summit Title: ARTEMIS ® Antibody TCR T Cell Therapies for Solid Tumors Speaker: Cheng Liu, Ph.D., President and CEO Date: Tuesday, October 27, 2020 Time: 9:00 a.m
-
Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma
10/5/2020
Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS ® T Cell Therapy in Hepatocellular Carcinoma
-
Eureka Therapeutics to Present at Oppenheimer's Private Life Sciences Company Call Series
6/25/2020
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that Dr. Cheng Liu, President and Chief Executive Officer, is scheduled to participate at Oppenheimer’s Private Life Sciences Company Call Series on Monday, June 29, 2020. Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS ® T cell) that has b
-
Eureka Therapeutics Completes $45 Million Series E Financing and Enters Into Strategic Collaboration With Lyell Immunopharma
3/17/2020
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies for solid tumors, today announced that it has closed a $45 million Series E financing. The round was led by Lyell Immunopharma and joined by a syndicate of new and prior investors. In addition to the financing, Eureka and Lyell have entered into a strategic collaboration to develop therapies against several undisclos
-
Eureka Therapeutics Announces Upcoming Conference Presentations in March 2020
3/3/2020
Eureka Therapeutics, Inc. announced that the company is scheduled to present at the following March healthcare conferences
-
Eureka Therapeutics to Present at 6th Annual Immuno-Oncology 360° Conference
2/20/2020
Feb. 20, 2020 13:00 UTC Eureka Therapeutics to Present at 6 th Annual Immuno-Oncology 360° Conference EMERYVILLE, Calif.--( BUSINESS WIRE )-- Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that President and CEO Dr. Cheng Liu will be presenting at the 6 th Annual Immuno-Oncology 360° Conference (IO360°) in New York on February 27, 2020. Dr. Liu will be presenting the use of Eureka’s n
-
Eureka Therapeutics to Present at the CAR-TCR Summit Europe
2/18/2020
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that its Director of Strategy and Business Development, Dr. Jingyi Xiang, will be presenting at CAR-TCR Summit Europe being held at the Novotel London West, London, United Kingdom on February 25, 2020.
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Chris Lehman Joins Avellino Labs As Chief Financial Officer
1/14/2020
Avellino Labs, global biotechnology and precision medicine innovators, announced that Chris Lehman has joined the company as Chief Financial Officer.
-
Eureka Therapeutics to Present New Clinical Data of anti-CD19 ARTEMIS™ 3.0 T-cell Therapy at 2019 ASH Annual Meeting
12/3/2019
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new clinical data from its first-in-human study of ET019003, an anti-CD19 T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), will be presented in a poster session at the 61st American Society of Hematology (ASH) Annual Meeting on December 8, 2019.
-
Eureka Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting
10/31/2019
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, announced a poster presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting, November 6-10, 2019, in National Harbor, Maryland.
-
Clinical Catch-up for August 5-9
8/12/2019
Last week was a particularly busy week for biopharma companies to release information about ongoing clinical trials. Here’s a look. -
Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of ET140202 ARTEMIS™ T-Cell Therapy in Liver Cancer
8/5/2019
Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced initiation of Phase 1/2 clinical trial of ET140202 ARTEMIS™ T-Cell therapy in liver cancer at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, based in Duarte, California.
-
Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating Selective Depletion of Tregs Using Foxp3 Targeting TCR-mimic Antibody
4/15/2019
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced the publication of a proof-of-concept study in OncoImmunology entitled “Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.”
-
Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating GPRC5D as a Promising Target for Antibody-Based Therapies in Multiple Myeloma
3/27/2019
Potential to target GPRC5D in multiple myeloma patients relapsed after BCMA-targeted therapy
-
BioSpace Movers and Shakers: Feb. 15
2/15/2019
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. -
EUREKA THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. HANZHONG LI AS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT
2/7/2019
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced the appointment of Hanzhong Li, Ph.D., M.B.A. as Senior Vice President of Corporate Development.
-
Eureka Therapeutics Announces US FDS Clearance of IND Application for Phase 1/2 Trial of ET140202 Artemis T-Cell Therapy, for the Treatment of Liver Cancer
1/30/2019
Eureka Therapeutics, Inc., a clinical stage biotechnology company developing antibody-TCR (AbTCR) T-cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ET140202 ARTEMIS™ T-cell therapy in AFP-positive patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer.
-
Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting
11/30/2018
Eureka Therapeutics, Inc., announced today that five abstracts, including four oral presentations and one poster discussion, highlighting clinical programs in multiple myeloma and NHL using binding domains developed by Eureka, have been accepted for presentation at the American Society of Hematology (ASH) Annual Meeting being held December 1-4 in San Diego, California